Firms
Theme

ROST

Ross Stores Inc · NASDAQ

↓ $7.37 (3.11%)

Last close · Oct 23, 4:00 PM ET

Sign up free to see this.

Mkt Cap
$73.3B
Volume
1.6M
52W High
$257.00
52W Low
$154.87
PE Ratio
27.6
Avg Vol
2M
As of 10/23/26
Div Yield
0.75%
Beta
0.54
As of 10/23/26

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

At least 5 tagged posts are needed.

How do you feel about ROST?

Latest news

News ›

Zacks Investment Research

Ross Stores (ROST) Stock Declines While Market Improves: Some Information for Investors

Ross Stores stock declined 1.29% to $234.18 while the broader market gained, underperforming the S&P 500's 0.58% rise. Despite the daily decline, the company is expected to report strong earnings growth of 15.19% EPS and 10.68% revenue growth. The stock holds a Zacks Rank #2 (Buy) rating, though it trades at a premium valuation with a Forward P/E of 27.05 compared to its industry average of 21.73.

Zacks Investment Research

Can DLTR's Multi-Price Strategy Drive Sustainable Sales Growth?

Dollar Tree's multi-price strategy drove Q2 FY26 comparable sales growth of 3.7%, with multi-price penetration reaching 17% of total sales. The company, along with Ross Stores, Dollar General, and Burlington Stores, is leveraging value-oriented retail models to attract customers across income levels. However, merchandise inflation and freight costs remain headwinds.

Zacks Investment Research

The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics

Zacks highlights five non-tech Nasdaq stocks with Zacks Rank #1 (Strong Buy) ratings positioned for Q4 gains. Ross Stores benefits from strong sales momentum and store expansion; Roku capitalizes on the shift from linear TV to streaming advertising; APA Corp offers favorable capital efficiency and long-term growth; Corcept Therapeutics sees strong demand for Korlym and new product launches; Halozyme benefits from collaboration royalties and milestone payments.

Headlines link to the publisher. Not investment advice.

Board · 0 threads

Open board ›

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $ROST · 0 threads

Sign in to post on $ROST

No threads yet

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev